Led · Equity · Jan 2018

SomaLogic develops and commercializes a proprietary proteomics platform built around its SOMAmer protein-binding reagents, which blend attributes of monoclonal antibodies and traditional aptamers. Its flagship SOMAscan assay currently deploys 1,310 different SOMAmer reagents to quantify proteins across a broad concentration range using small sample volumes from multiple biological matrices. These capabilities provide researchers and clinicians with powerful tools for protein biomarker discovery, diagnostics development, and pharmaceutical innovation. The company is led by Chief Executive Officer Byron Hewett and Founder & Chairman Larry Gold, PhD. SomaLogic plans to expand its portfolio of life-science tools and clinical diagnostic products that leverage its core technology. To finance this growth, it is arranging up to $60.5 million in combined debt and equity financing from Visium Healthcare Partners, strengthening its balance sheet for continued R&D and commercialization efforts.

Participated · Equity · May 2017

HealthLoop is a patient engagement and care coordination business based in Mountain View, California. Its platform supports post-hospitalization follow-up and gathers patient-related outcomes after surgery, tracking physical therapy and home care visits. The company says its software improves communication between physicians and patients and has reduced adverse events and surgical complications. HealthLoop serves a mix of middle-market, single-specialty practices and hospitals, counting more than 70 hospitals and medical groups as customers. Financially, the company has completed the first close of an $8.4 million financing round and is expanding sales and marketing/commercial teams with the proceeds. It cites the CMS bundled payment program for joint replacement as a growth driver and sees applications of its platform for chronic conditions such as COPD, congestive heart failure, and diabetes. HealthLoop offers a cloud-based platform that automates how doctors engage with patients after visits, delivering clinical information and peer-reviewed follow-up plans. Its analytics engine parses patient data in real time to surface patients and clinical issues that require attention. The product aims to extend the doctor–patient relationship outside the exam room, reduce unnecessary in-office visits, and improve outcomes while saving doctors time. HealthLoop positions itself as complementary to EHRs and PHRs by focusing on realtime, actionable follow-up and patient monitoring. The company was founded by Dr. Jordan Shlain out of frustration with unreported symptoms between visits. With new funding, HealthLoop plans to ramp hiring, expand development of patient engagement and follow-up tools, and raise awareness among doctors.

Led · Equity · Jan 2017

PatientsLikeMe is the world’s largest integrated community, health management, and real‑world data platform that lets members share personal stories, symptoms, treatments, and outcomes. A growing community of more than 830,000 people across over 2,900 conditions contributes self‑reported data used to monitor symptoms, quantify outcomes, and provide peer support. The platform aggregates these real‑world data to support care delivery, scientific research, consumer engagement, and clinical trials, and the company cites more than 100 studies in peer‑reviewed medical and scientific journals. PatientsLikeMe plans to expand its support and empowerment of people managing significant health conditions and to accelerate partnerships with care delivery organizations, health plans, employers, pharmacies, PBMs, life‑sciences organizations, and government sponsors. The company is entering a new phase of growth as an independent, venture‑backed organization and will use new funding to scale those efforts. The recent financing is intended to broaden the platform’s capacity for patient engagement, research, and care‑management solutions. PatientsLikeMe operates a personalized digital platform that collects and aggregates patient-generated health data to give patients real-world context for decision-making and outcome improvement. The platform is used by more than 500,000 people to track and share information about roughly 2,700 conditions. More than 40 pharmaceutical companies and numerous government organizations have collaborated with PatientsLikeMe and used its data for research and product development. The company has published more than 100 research studies based on patient-generated health data. PatientsLikeMe is led by CEO Martin Coulter and was co-founded by Ben and Jamie Heywood and Jeff Cole. Through a new strategic partnership with iCarbonX the company plans to apply next-generation biological measures and machine learning, with iCarbonX providing multi-omics characterization services.

Led · Equity · Jan 2017

AOBiome develops a novel class of therapeutics based on ammonia-oxidizing bacteria (AOB) that consume ammonia and produce nitrite and nitric oxide, signaling molecules that regulate inflammation and vasodilation. The company sells consumer biome-friendly products under the Mother Dirt brand while advancing clinical-stage drug candidates. AOBiome is pursuing host-regulated drug approaches and positions its AOB platform as a potential first FDA‑approved therapy of this type. The company has launched a Phase 2 clinical trial for hypertension and initiated a Phase 2B acne vulgaris trial. AOBiome frames its work within a “Germ Theory of Health,” aiming to repopulate keystone commensal bacteria lost through modern hygiene. It operates from Boston and San Francisco and was founded in 2013.